Newer Drugs Offset Generic Pressure at Bayer
Healthcare operators should watch how branded launches absorb patent-expiry losses on legacy products like Xarelto.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you trust large drugmakers to put patients ahead of profits?
Bayer AG raised its annual adjusted EBITDA outlook to €9.8 billion–€10.3 billion after third-quarter earnings of €1.62 billion beat the average analyst estimate surveyed by Bloomberg. The gain was led by its pharmaceutical unit, where demand for newer drugs Nubeqa and Kerendia offset generic pressure on Xarelto and Eylea.
Why it matters
For operators in healthcare and pharma supply chains, the result shows that demand for newer, branded therapies can outrun the erosion from generic competition on older products. Management attributed the strength to rising demand for newer drugs rather than to price or volume changes in legacy lines, a shift that affects how distributors and providers plan inventory and contracting.
Bayer's new adjusted EBITDA range of €9.8 billion–€10.3 billion sits slightly above its prior forecast, and third-quarter earnings of €1.62 billion topped analyst expectations. Nubeqa sales reached about €1 billion in the quarter, while Xarelto sales fell 30%, and the company has paid more than US$11 billion to resolve Roundup claims.
The players
Bayer AG
A German life sciences company with pharmaceutical and crop science divisions, selling prescription drugs and crop-protection products worldwide.
Bloomberg
A global financial data and news company whose surveyed analyst estimates are widely used as a benchmark for corporate earnings expectations.
The details
The pharmaceutical unit's sales and profit growth were strong enough to offset generic competition hitting Xarelto and Eylea. Bayer's crop science division moved the other way, with earnings down 41% in the quarter, driven partly by higher costs and weaker crop-protection sales. The company has also pledged to significantly contain its legal overhang on Roundup by the end of this year, after a favourable US Supreme Court ruling in June.
Timeline
June: US Supreme Court issued a favourable ruling for Bayer on Roundup.
Earlier this year: Bayer separated its US glyphosate business into Ruveon.
Third quarter: Pharmaceutical division sales and profit growth were reported.
3 November 2026: Bayer raised its annual profit outlook.
End of this year: Bayer targets significant containment of its legal overhang.
Market Landscape
The result follows the June US Supreme Court ruling on Roundup and Bayer's earlier separation of its US glyphosate business into Ruveon. It also reflects a broader pattern in which branded pharma launches absorb the loss of revenue from patent-expired franchises such as Xarelto.
Operators in pharmaceutical distribution and healthcare procurement should expect continued demand for newer branded therapies while watching for margin pressure on older products facing generic entry. Businesses with exposure to crop-protection supply should note the 41% earnings decline in that segment as a signal of cost and demand pressure.
The takeaway
Growth in newer branded drugs can outweigh generic erosion on legacy products, so healthcare operators should track branded launch performance against patent-expiry timelines. Review your exposure to legacy therapies and reassess contract terms with qualified counsel or an accountant where payer or pricing commitments are involved.
Further reading
For more on how branded drug launches are reshaping the sector, see our Healthcare coverage.
Live Poll
Do you trust large drugmakers to put patients ahead of profits?
